BIONXT SOLUTIONS INC. (BXT) - Total Assets
Based on the latest financial reports, BIONXT SOLUTIONS INC. (BXT) holds total assets worth €1.23 Million EUR (≈ $1.43 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore BXT cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
BIONXT SOLUTIONS INC. - Total Assets Trend (2021–2024)
This chart illustrates how BIONXT SOLUTIONS INC.'s total assets have evolved over time, based on quarterly financial data. See BXT net assets for net asset value and shareholders' equity analysis.
BIONXT SOLUTIONS INC. - Asset Composition Analysis
Current Asset Composition (December 2024)
BIONXT SOLUTIONS INC.'s total assets of €1.23 Million consist of 28.8% current assets and 71.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 5.7% |
| Accounts Receivable | €60.60K | 10.6% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how BIONXT SOLUTIONS INC.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BXT stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BIONXT SOLUTIONS INC.'s current assets represent 28.8% of total assets in 2024, an increase from 27.8% in 2021.
- Cash Position: Cash and equivalents constituted 5.7% of total assets in 2024, down from 13.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 60.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 10.6% of total assets.
BIONXT SOLUTIONS INC. Competitors by Total Assets
Key competitors of BIONXT SOLUTIONS INC. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
|
China | CN¥2.30 Billion |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
China | CN¥8.59 Billion |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
|
China | CN¥925.41 Million |
|
Jw Pharmac
KO:001060
|
Korea | ₩605.27 Billion |
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Samjin Pharm
KO:005500
|
Korea | ₩449.14 Billion |
BIONXT SOLUTIONS INC. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.22 | 0.04 | 0.04 |
| Quick Ratio | 0.22 | 0.04 | 0.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-3.06 Million | €-7.82 Million | €-7.82 Million |
BIONXT SOLUTIONS INC. - Advanced Valuation Insights
This section examines the relationship between BIONXT SOLUTIONS INC.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 22.68 |
| Latest Market Cap to Assets Ratio | 48.03 |
| Asset Growth Rate (YoY) | -55.1% |
| Total Assets | €569.36K |
| Market Capitalization | $27.35 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values BIONXT SOLUTIONS INC.'s assets at a significant premium (48.03x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: BIONXT SOLUTIONS INC.'s assets decreased by 55.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BIONXT SOLUTIONS INC. (2021–2024)
The table below shows the annual total assets of BIONXT SOLUTIONS INC. from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €569.36K ≈ $665.64K |
-55.08% |
| 2023-12-31 | €1.27 Million ≈ $1.48 Million |
-21.40% |
| 2022-12-31 | €1.61 Million ≈ $1.89 Million |
-83.42% |
| 2021-12-31 | €9.73 Million ≈ $11.37 Million |
-- |
About BIONXT SOLUTIONS INC.
BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis; BNT23002 for the treatment of myasthenia gravis; BNT24002, a sublingual thin film for the treatment of lupus nephritis; BNT24003 for the treatment of rheum… Read more